Lee Pharmaceuticals (LPHM) 0.0150 $LPHM
Investigation Report on China's Insulin Lispro Market, 2009-2018
M2 - Wed Mar 19, 9:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2w4ssh/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2009-2018" report to their offering. According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 382 million patients worldwide. The number of diabetes patients in China was more than 98 million, ranking the first in the world. The rapid growth of diabetes patients is becoming a serious economic and social issue in China and other developing countries. The first ultra-short-acting human insulin analogue insulin lispro (produced by Eli Lilly and Company with the trade name ""Humalog""
was launched in 1996 and approved by FDA. Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion. Humalog was launched in China in 2005 and its annual sales revenue continues to grow rapidly. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin lispro in Chinese hospitals grew more than 100 times from 2005 to 2013. Most of the market is occupied by Eli Lilly and Company while the other belongs to Gan & Lee Pharmaceuticals. There used to be legal disputes between the two companies over the patent of insulin lispro in China. Based on CRI's investigation, insulin lispro produced by other Chinese enterprises will soon appear on the market. Key Topics Covered: 1 Relevant Concepts of Insulin Lispro 2 Market Overview of Insulin Lispro in China 3 Investigation on Sales Value of Insulin Lispro in China, 2009-2013 4 Investigation on Market Share of Major Insulin Lispro Manufacturers in China, 2009-2013 5 Investigation on Market Size of Insulin Lispro by Dosage Form in China, 2009-2013 6 Reference Price of Insulin Lispro Produced by Different Enterprises in China Hospital Market, 2014 7 Major Manufacturing Enterprises in China Insulin Lispro Market, 2009-2013 8 Prospect of China Insulin Lispro Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/2w...estigation
Investigation Report on China's Insulin Glargine Market to 2018
M2 - Thu Mar 06, 11:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/tgjsv7/investigation) has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" report to their offering. In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition. The CAGR (compound annual growth rate) of sales value of insulin glargine in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap, so manufacturers have to attain an industrial production of large scale, low cost and mature technology before gaining profit. As Chinese people's living standard improves and lifestyles change, incidence of diabetes continuously goes up, resulting in the year-after-year expanding of diabetes drug market in the country. According to CRI's investigation, total sales value of diabetes drug market in China surpassed CNY 18 billion in 2013. In China, the second-generation recombinant human insulin is still the market mainstream. However, as the third-generation insulin products are more technically advanced comparing with the second-generation by diminishing certain defects and shortening curing time effectively, it is expected to replace the second-generation in the near future. As a product with most growth potential among the three generations of insulin products in China, insulin glargine is expected to get more and more attention. Key Topics Covered: 1 Relevant Concepts of Insulin Glargine 2 Market Overview of Insulin Glargine in China 3 Investigation on Sales Value of Insulin Glargine in China, 2009-2013 4 Investigation on Market Share of Major Insulin Glargine Manufacturers in China, 2009-2013 5 Investigation on Market Size of Insulin Glargine by Dosage Form in China, 2009-2013 6 Reference Price of Insulin Glargine in Hospital Market in China, 2013 7 Major Manufacturing Enterprises in China Insulin Glargine Market, 2009-2013 8 Prospect of China Insulin Glargine Market, 2014-2018 Companies Mentioned - Aventis Behring GmbH - Gan & Lee Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tg...estigation
China Insulin Industry Report, 2012-2015
M2 - Wed Jan 23, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/48k59t/china_insulin) has announced the addition of the "China Insulin Industry Report, 2012-2015" report to their offering. Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so. Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China's insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011. Key Topics Covered: 1. Insulin Overview 1.1 Definition 1.2 Classification 1.3 Industry Chain 2. Global Insulin Market Development 2.1 Status Quo 2.2 Supply and Demand 2.3 Product R&D 2.
Investigation Report on China's Insulin Lispro Market, 2009-2018
M2 - Wed Mar 19, 9:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2w4ssh/investigation) has announced the addition of the "Investigation Report on China's Insulin Lispro Market, 2009-2018" report to their offering. According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 382 million patients worldwide. The number of diabetes patients in China was more than 98 million, ranking the first in the world. The rapid growth of diabetes patients is becoming a serious economic and social issue in China and other developing countries. The first ultra-short-acting human insulin analogue insulin lispro (produced by Eli Lilly and Company with the trade name ""Humalog""
was launched in 1996 and approved by FDA. Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion. Humalog was launched in China in 2005 and its annual sales revenue continues to grow rapidly. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin lispro in Chinese hospitals grew more than 100 times from 2005 to 2013. Most of the market is occupied by Eli Lilly and Company while the other belongs to Gan & Lee Pharmaceuticals. There used to be legal disputes between the two companies over the patent of insulin lispro in China. Based on CRI's investigation, insulin lispro produced by other Chinese enterprises will soon appear on the market. Key Topics Covered: 1 Relevant Concepts of Insulin Lispro 2 Market Overview of Insulin Lispro in China 3 Investigation on Sales Value of Insulin Lispro in China, 2009-2013 4 Investigation on Market Share of Major Insulin Lispro Manufacturers in China, 2009-2013 5 Investigation on Market Size of Insulin Lispro by Dosage Form in China, 2009-2013 6 Reference Price of Insulin Lispro Produced by Different Enterprises in China Hospital Market, 2014 7 Major Manufacturing Enterprises in China Insulin Lispro Market, 2009-2013 8 Prospect of China Insulin Lispro Market, 2014-2018 For more information visit http://www.researchandmarkets.com/research/2w...estigation Investigation Report on China's Insulin Glargine Market to 2018
M2 - Thu Mar 06, 11:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/tgjsv7/investigation) has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" report to their offering. In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition. The CAGR (compound annual growth rate) of sales value of insulin glargine in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap, so manufacturers have to attain an industrial production of large scale, low cost and mature technology before gaining profit. As Chinese people's living standard improves and lifestyles change, incidence of diabetes continuously goes up, resulting in the year-after-year expanding of diabetes drug market in the country. According to CRI's investigation, total sales value of diabetes drug market in China surpassed CNY 18 billion in 2013. In China, the second-generation recombinant human insulin is still the market mainstream. However, as the third-generation insulin products are more technically advanced comparing with the second-generation by diminishing certain defects and shortening curing time effectively, it is expected to replace the second-generation in the near future. As a product with most growth potential among the three generations of insulin products in China, insulin glargine is expected to get more and more attention. Key Topics Covered: 1 Relevant Concepts of Insulin Glargine 2 Market Overview of Insulin Glargine in China 3 Investigation on Sales Value of Insulin Glargine in China, 2009-2013 4 Investigation on Market Share of Major Insulin Glargine Manufacturers in China, 2009-2013 5 Investigation on Market Size of Insulin Glargine by Dosage Form in China, 2009-2013 6 Reference Price of Insulin Glargine in Hospital Market in China, 2013 7 Major Manufacturing Enterprises in China Insulin Glargine Market, 2009-2013 8 Prospect of China Insulin Glargine Market, 2014-2018 Companies Mentioned - Aventis Behring GmbH - Gan & Lee Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tg...estigation
China Insulin Industry Report, 2012-2015
M2 - Wed Jan 23, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/48k59t/china_insulin) has announced the addition of the "China Insulin Industry Report, 2012-2015" report to their offering. Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so. Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China's insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011. Key Topics Covered: 1. Insulin Overview 1.1 Definition 1.2 Classification 1.3 Industry Chain 2. Global Insulin Market Development 2.1 Status Quo 2.2 Supply and Demand 2.3 Product R&D 2.
